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ABSTRACT 
Objective: Studies have shown that mental health is affected by poor physical health, with people living in the deprived area are the most affected. 
Community Pharmacists potentially have a new role in supporting people with mental illness and dementia to manage their medications. The aim of 
this local audit was to compare the local population to the national and global population, to inform the development and provision of local 
pharmacy mental health screening services, to support patients diagnosed with long-term conditions. 
Methods: This project was designed as an audit of anonymised local data, to inform the development of services offered by community pharmacies 
to improve adherence to therapy amongst patients diagnosed with long-term conditions in the Black Country, UK. It forms part of a larger study 
granted ethical approval by the Health Research Authority in 2018. It was carried out against the background of the Covid-19 epidemic. A total of 
652 patients pharmacy records were reviewed between March and April 2020. No patient identifiers were included in the reviewed data. 
Results: This means that the results of this analysis might not be applicable to the entire local population outside the 31-90 y of age range. 
Conclusion: It is was demonstrated during COVID-19 that pharmacists are well-positioned as easily accessible health care facilities to support 
patients, especially when the other NHS facilities are stretched or closed. Community pharmacies are in a position to offer large-scale screening 
programs such as self-completed anxiety, depression and cognitive function screening surveys and refer to general practitioners for further 
investigations. It is also recommended that the New Medicines Service include mental health disorder patients prescribed pharmacological therapy 
and to allow the pharmacists appropriate access to medical records to facilitate safe, integrated and effective patient care.  
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INTRODUCTION 
The effect of mental ill-health (MIH) on an individual’s quality of life 
and ability to self-care their other long-term conditions cannot be 
ignored [1]. Medications to manage MIH are dispensed by 
community pharmacies with many patients taking antipsychotic and 
anti-depressant drugs [1]. The community pharmacy workforce 
have the most contact with patients, as they are easily accessible and 
well-placed within the community [2]. According to the Royal 
Pharmaceutical Society (RPS), one in six adults in the United 
Kingdom (UK) experience at least one diagnosable MIH problem at 
any given time, with a life-time incidence of 1 in 4 [1]. MIH has been 
identified by the Department of Health (DoH) as the third-ranked 
illness category affecting the nation’s health [2]. Studies have shown 
that MIH is affected by poor physical health, with people living in 
deprived areas most affected [3]. People who have MIH have been 
shown to be at great risk of cardiovascular diseases (CVD) and vice 
versa; where people diagnosed with CVDs and diabetes have 
increased risk of depression, anxiety and some types of dementia 
[3]. People with long-term conditions attend community pharmacies 
regularly for ongoing supplies and can be supported by the 
pharmacy workforce. MIH is multifaceted and influenced by a wide 
range of economic, social, physical, environmental and individual 
factors. According to The World Health Organisation (WHO), ‘People 
with mental disorders experience disproportionately higher rates of 
disability and mortality’ [4]. Globally, the disparity between the need 
for treatment and receiving that treatment is large as health systems 
have not yet caught up with the increase in people reaching out for 
mental health support [4]. Currently, community pharmacies are not 
part of the MIH support effort and many community pharmacists 
and their staff are lacking MIH awareness and training [4]. The 
vision of the WHO action plan of 2012-2020 was a world in which 
mental health is valued, promoted and protected. Their goal is 
nations working to create a world where MIH is prevented and those 
affected receive treatment rendering them able to enjoy their human 
rights through access to timely, high quality, culturally-appropriate 
health and social care to promote recovery within a society free 
from stigmatization and discrimination [4, 5]. According to the 
Mental Health Foundation, only 13% of the population reported 
living with high levels of good mental health [5]. Household income 
and economic activity play a major part in mental health state; three 
out of four people in the UK living in the lowest household income 
bracket (less than £1,200 per month) report having experienced a 
MIH compared to 6 in 10 of the highest household income bracket 
(over £3,701 pm) [5]. The majority (85%) of unemployed people 
experience MIH problems compared to 66% of employed people and 
just 50% of retirees. This rises to seven in 10 women, young adults 
(18-34 y old) and people living alone [5]. The mental health policy 
group manifesto highlighted that people with MIH problems may be 
susceptible to increased risk of developing chronic physical health 
problems. This is due to the effects of medication such as 
antipsychotics and antidepressants prescribed to treat MIH, with 
one in three of 100,000 ‘avoidable deaths’ annually, is people with 
MIH [6]. In comparison to the general population, people with 
serious MIH experience a higher risk of diabetes (up to 2X), 
hypertension (up to 3X), dying from coronary heart diseases (up to 
3X), deaths from respiratory diseases for people with schizophrenia 
(up to10X) and dying prematurely under the age of 50 (4X) [6].  
Community pharmacists could also potentially have a role in 
supporting people with dementia and their carers to manage their 
medications and contribute to the early detection of dementia [7]. 
The impact that Pharmacists and their teams can have in supporting 
people with dementia has been nationally recognized; hence the 
requirement for the ‘healthy living pharmacy’ workforce to be 
‘Dementia Friends. 
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Approximately one in three GP Appointments relate to MIH; 
however, the provision of treatment can continue long after the 
diagnosis [5]. MIH receives 5.8% of the total UK health research 
budget but represents 23% of service demand [3]. There is a need to 
make healthcare more accessible to everyone and to reduce health 
inequalities among communities, especially within health postcodes 
and deprivation indexes [8]. The NHS ‘Five Year Forward View’ 
identified mental health as the cause of disability for one in every 
four people at some point of their life [9]. More than 16 million 
people in England are diagnosed with long-term physical health 
condition and according to the NHS, one out of three of those will 
experience MIH [10]. 
Pharmacists have a role to play in health promotion, to create 
awareness about MIH. Wheeler et al. concluded it would be a missed 
opportunity for policymakers not to consider using the skills of the 
community pharmacy workforce to support mental health services 
[11]. Another study estimated that around 50% of people living with 
long-term conditions do not adhere to taking their medication after 
a period of six months. They estimated this cost the USA around 
US$300 billion annually [12]. It is important that prescribers spend 
time discussing adherence to their medication with their patients 
and factors that may influence this. However, with a stretched NHS 
and limited resources to enable prescribers to spend more time with 
patients, it is important that healthcare professionals support each 
other in optimising the patients’ journey and experience [13]. The 
pharmacy workforce are well-placed to identify non-adherence early 
and to support or signpost the patient to the right professionals [12]. 
In the UK, only 24% of those with a common mental health problem 
and 65% of those with psychotic problems have received any 
treatment, in comparison 91% of people with hypertension and 94% 
of people with diabetes [14].  
Medicine use review (MUR) is a service provided by community 
pharmacists. People with MIH are known to have difficulty with 
adherence to their medication regimen [12, 14]. In addition to their 
knowledge about medications, undertaking mental health first aid 
(MHFA) training empowers the pharmacy workforce to recognize 
the early signs of MIH and to have the confidence to provide the 
appropriate initial help. One of the recommendations the mental 
health five-year forward view is for people with MIH to have quick 
access to evidence-based care for the biological, psychological and 
social issues related to their needs, in the least restrictive setting and 
as close to home as possible [15].  
Medication used in treating long term conditions including MIH has 
different side effects, of which some are serious [16]. Pharmacists 
can identify these through the use of the new medicine service 
(NMS) available at their UK community pharmacies. The NMS was 
introduced in England in 2011, to support people who are starting a 
new medication for their long-term condition [17]. Four specific 
patient groups were found to be affected and experienced a 
reduction in the rate of hospital admissions. These are patients 
diagnosed with asthma or chronic obstructive pulmonary disease 
(COPD), hypertension (HTN), Type 2 diabetes mellitus (T2DM), or 
those who had a prescription of anticoagulant and antiplatelet 
agents [17]. The service is carried out at the community pharmacy 
where the patient collects their medication for the first time. 
Problems encountered when patients first start taking their 
medication can lead to the patient ceasing the medication [17, 18]. 
Early side effects may lead to many patients to stop taking their 
medications as prescribed or for the full duration for which they are 
prescribed. The NMS provides an avenue for the pharmacist to 
support the patient through providing information and support on 
their medication and treatment and also provide an early referral to 
the prescriber if the medication proves unsuitable or if the side 
effect will require discontinuing the medication [17, 18]. To 
participate in the NMS service, patients give their written consent by 
signing a prepopulated, approved form while presenting the 
prescription for the first time at their pharmacy. The patients then 
receive a consultation with the community pharmacist 7-14 d after 
starting their medication and then another follow-up consultation 
between 14-21 d after starting. This can be performed either face to 
face, or over the telephone. The pharmacy can identify adherence 
behaviour at this point and provide support to improve adherence, 
ensuring that the medication benefit is optimised ensuring the 
efficient use of the NHS resources [17-19]. Without a means to 
identify whether a patient is taking their medication and the reason 
for non-adherence (unintentional due to forgetfulness or 
intentional/deliberate) their benefit from those medications will be 
limited [19].  
More than 15 million people in England (30% of the population) 
have one or more long-term medical conditions [20]. Many of these 
also experience MIH, which represents one of the top three causes of 
death in the UK [15, 19]. People living with diabetes and COPD are 
three times more likely to have depression than the general 
population [19]. Up to 33% of women and more than 20% of men 
with all types of arthritis also may have co-morbid depression [20]. 
It is estimated that long-term conditions account for around 70% of 
total UK spending on health, of which £8-£13 billion are for MIH 
alone [19]. The role of the pharmacist in providing early support to 
people with long-term conditions and early identification of MIH 
could be beneficial in the management of their disease and 
compliance with their medication [15, 19]. 
Early identification of MIH is crucial to the provision of effective 
support for people with long-term conditions and may contribute to 
reducing the excess costs associated with complications [19]. Nine 
out of ten people with MIH are treated in primary care and 90% of 
adults with severe mental health problems are also supported by 
community services [15]. The RPS recommends the skills and 
expertise of pharmacists should be utilised in the multidisciplinary 
management of patients with MIH, especially in the community [16]. 
Most deprived areas in the UK usually have access to community 
pharmacies, which are easily accessed with longer opening hours 
than many medical practices and no need for pre-booked 
appointments. Many people with long-term conditions who are also 
living with MIH live in deprived areas with access to fewer resources 
of all kinds, as manifested as clear health inequalities [19]. The 
King’s Fund recommended that Clinical commissioning groups 
(CCGs) should prioritise integrating mental and physical health care 
more closely as a key part of their improvement strategies [19]. 
It is estimated that there are >900,000 adults (aged 18 and older) 
with intellectual disabilities in England (2013 census data), with 
350,000 people registered as blind or partially sighted [20]. People 
living with sensory impairments have a greater lifetime risk of 
developing MIH [20]. According to WHO, MIH and substance use 
disorders are the leading cause of disability worldwide causing 
about 23% of all years lost due to disability [20]. This accounts for 
23% of the total ‘burden of disease’ in the United Kingdom [19]. 
They also represent the leading cause of disability in children and 
young people globally [21]. Public Health England (PHE) estimates 
that, in 2015, up to 35,000 adults with a learning disability were 
prescribed an antipsychotic medication, an antidepressant or both, 
without appropriate clinical justification [19]. People with learning 
disabilities may have difficulty identifying important symptoms and 
gaining initial access to appropriate care. They may also find it 
difficult to correctly take medications that have long and complex 
instructions and which use inaccessible language [22]. Since 31st 
July 2016, pharmacists are required to comply with the Accessible 
Information Standard, which requires providers of NHS and adult 
social care to identify, record, flag, share and meet the information 
and communication support needs of people with a disability or 
sensory loss [23]. The UK Action on Hearing Loss estimates that 
more than 9 million people in England have some form of hearing 
loss, projected to be 15.6 million by 2035 [23]. The impact of MIH in 
the workplace affects both the individual and the productivity of the 
entire organization [24]. According to the UK DoH and the 
Confederation of British Industry, 15-30% of workers will 
experience some form of MIH during their working lives. In the UK, 
80 million days are lost annually due to MIH, costing employers £1-2 
billion each year. Those in the poorest 20% of the UK population are 
twice as likely to develop MIH compared to those on an average 
income [24]. 
Aim 
The aim of this local audit was to compare the local population to the 
national and global population, to inform the development and 
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provision of local pharmacy MIH screening services to support 
patients diagnosed with long-term conditions. 
MATERIALS AND METHODS 
This project was designed as an audit of anonymised local data, to 
inform the development of services offered by community 
pharmacies to improve adherence to therapy amongst patients 
diagnosed with long-term conditions in the Black Country, UK. The 
audit forms part of a larger study, granted ethical approval by the 
Health Research Authority in 2018. A total of 652 patients' 
pharmacy records were reviewed between March and April 2020. 
There were no patient identifiers included in the reviewed data, 
which was analysed using Microsoft® Excel™. 
RESULTS 
Table 1 shows the local population ethnicity by age group, where the 
majority of patients are white (94%). This is representative of the local 
population census data of 90%. The second-largest ethnic group was 
Asian of 6% compared to 5.6% of the population and 1.8% Black 
people compared to 1.7% of the population of the borough. The 
majority of the records (90%) were for patients between the age of 31 
and 90 (31-50 y of age at 29%, 51-70 y of age at 38%, 71-90 y of age at 
22%). Compared to the local population of 64% from the same age 
group; (22.5%, 27.5% and 14%, respectively). This means that the 
results of this analysis might not be applicable to the entire local 
population outside the 31-90 y of age range. 
The number of patients in each medical disorder category was 
counted (table 2). The highest number of medical conditions 
identified in a white person’s records was 12 in a 53 y old, one of 
which was MIH this was followed by an Asian 60 y old of 10 
conditions of which one was a mental illness and 6 conditions in a 
black 65 y old person and no mental illness. This further highlights 
the unique characteristics of health determinants and service 
utilisation for different ethnicity, where in the UK black and Asian 
are grouped under black and minority ethnic (BAME) group. 
 
Table 1: Ethnicity by age group 
Age in years Asian Black White 
18-30 4 1 63 
31-50 18 2 170 
51-70 8 4 233 
71-100 2 1 146 
 
Table 2: Number of patients diagnosed with long-term conditions by body system 
Age in years 18-30 31-50 51-70 71-100 Total  
Cardiovascular disorders 5 69 141 117 332 
Pain and central nervous system disorders 17 80 100 63 260 
Mental disorders  28 91 86 28 233 
Gastrointestinal disorders 5 41 84 70 200 
Respiratory disorders 16 54 67 41 178 
Endocrine disorders 5 24 40 37 160 
Vitamins and minerals deficiencies 4 21 39 43 107 
Infection 9 23 34 22 88 
Genitourinary disorders 6 18 24 35 83 
Musculoskeletal disorders 2 18 33 23 76 
Eye/ear/nose/throat 3 11 20 27 61 
Skin 3 12 21 18 54 
Others 0 3 7 2 12 
Oncology  0 2 4 4 10 
 
The mean number of medications per age group was then calculated. 
The highest number of medications used was in the 31-50 y group, 
followed by the 51-70 y, 71-100 y and lastly was the 18-30 y of age 
groups (table 3). 
  
Table 3: Mean number (and range) of medications per person by age group 
Age in years Mean (range) of total number of medications Mean (Range) of number of medications for mental disorders 
18-30 n=68 6.5 (0-12) 1.5 (0-3) 
31-50 n=190 14.5 (1-28) 2.5 (0-4) 
51-70 n=245 16.5 (1-32) 2 (0-3) 
71-100 n=149 8 (1-17) 2 (0-3) 
 
Table 4 shows the mean number of medications per ethnicity. There 
was no significant difference between the groups. However, in the 
black group, there was no use of MIH medications, which may 
indicate under utilisations of services, while in the Asian group there 
was higher utilization than both white and black population. This 
requires further investigation. The highest number of medications 
used by one person was 32, where one patient had 31 for long-term 
conditions and one for MIH (Asian–60 y of age), followed by a white 
patient (45 y of age) who had 28 medications for long-term 
conditions and three medications for MIH. 
 
Table 4: Mean number (and range) of medications per person per ethnicity 
Ethnicity Mean of total number of medications Mean of medications for mental disorders 
Asian n=32 4.2 (1-32) 1 (0-1) 
Black n=8  3.5 (1-10) 0 (0) 
White n=612 4.7 (1-28) 0.4 (0-3) 
 
Medications from different categories were further analysed. 
Common side effects which may impact the long-term conditions 
patients MIH or cognitive function were documented (table 5). From 
the top 50 medications, 64% (n=32) have mood-affecting side effects 
including anxiety, depression, altered mood, sleep disorders, 
depersonalisation, abnormal dreams, depression, mania, psychotic 
disorders, hallucinations and suicidal ideation. There were 36% 
(n=18) medications with anticholinergic side effects that affect 
cognition (impaired concentration, memory loss and confusion). 
Additionally, there were 18% (n=9) of medications can cause 
hyponatraemia which may lead to cognitive issues (amongst many 
other issues) when severe and overlooked. 
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Table 5: Top 5 medications by system 
Disorders Patients 
number 
Mood side effects Hyponatremia and anticholinergic burden  
Mental disorders 
Citalopram 49 Anxiety, sleep disorders, depersonalisation  Hyponatremia, impaired concentration, confusion (ACB=1) 
Sertraline 49 Anxiety, sleep disorders, depersonalisation  Hyponatremia, impaired concentration, confusion (ACB=2)  
Mirtazapine 36 Anxiety, sleep disorders  Hyponatremia, impaired concentration, confusion (ACB=1) 
Fluoxetine 32 Anxiety, sleep disorders Hyponatremia, impaired concentration, confusion (ACB=1) 
Diazepam 17 Anxiety, depression, altered mood, sleep 
disorders, suicidal ideation 
Incoordination, confusion (ACB=1) 
Endocrine-diabetes  
Metformin 59   
Gliclazide 22 Depression, anxiety, headache, nervousness   
Insulin combined 20   
Alogliptin 8   
Empagliflozin 7   
Gastro-Intestinal  
Lansoprazole 101 Depression, sleep disorders Hyponatremia, confusion (ACB=1) 
Omeprazole 53 Depression, sleep disorders Hyponatremia, confusion (ACB=1) 
Laxative combined 28  Electrolyte abnormalities 
Mebeverine 7   
Ranitidine 6 Depression, hallucination Confusion (ACB=1) 
Cardiovascular     
Atorvastatin 126 Depression, sleep disorders Memory loss, confusion (ACB=1) 
Bisoprolol 84 Depression, hallucination, sleep disorders Confusion (ACB=1) 
Ramipril 76 Sleep disorders Electrolyte abnormalities 
Aspirin 68   
Amlodipine 64 Depression   
Respiratory     
Salbutamol  118   
Beclomethasone 
dipropionate 
38 Anxiety   
Beclomethasone/ 
formoterol 
31 Anxiety  
Budesonide/formoterol 25 Anxiety, sleep disorders  
Fluticasone/formoterol 19 Anxiety, sleep disorders  
Central Nervous    
Codeine/Paracetamol  99 Euphoric mood, hallucination Confusion (ACB=1) 
Paracetamol 46   
Gabapentin 35 Depression, sleep disorders  
Pregabalin 21 Altered mood, anxiety, hallucination Impaired concentration, memory loss, confusion (ACB=1) 
Zopiclone 19 Anxiety, depressed mood, depression, 
hallucination, sleep disorders 
Cognitive disorder, impaired concentration, delusions 
(ACB=1) 
Infections    
Doxycycline 24   
Clarithromycin 10 Depersonalisation, abnormal dreams, 
depression, mania, psychotic disorders 
 
Amoxicillin 8   
Flucloxacillin 6   
Phenoxy-methyl 
penicillin  
4   
Other Endocrine  
Levothyroxine 56 Anxiety, sleeping disorders  
Prednisolone 32 Anxiety, sleeping disorders, behaviour 
abnormalities, altered mood  
Electrolyte imbalance, cognitive impairment (ACB=1) 
Carbimazole 5   
Estradiol 3 Anxiety, depression   
Conjugated Oestrogens  2 Anxiety, depression, altered mood  
Genito-Urinary 
Doxazosin 25 Anxiety, depression, sleep disorders  
Tamsulosin 11   
Finasteride 9   
Solifenacin 9 Hallucination  Confusion (ACB=3) 
Desogestrel 8 Depressed mood, altered mood   
Others 
Quinine 20  Confusion (ACB=1) 
Naproxen 16 Depression, hallucination, sleep disorders Impaired concentration, confusion (ACB=1) 
Allopurinol 14 Depression   
Diclofenac 11 Anxiety, depression, sleep disorders Memory loss, confusion (ACB=1) 
Alendronic acid 8   
*According to FOX et al. (2011) [25] anticholinergic burden (ACB) defined as: Drugs with possible anticholinergic effects were defined as those with 
serum anticholinergic activity or in vitro affinity to muscarinic receptors but with no known clinically relevant negative cognitive effects (ACB score 
= 1). Drugs with established and clinically relevant cognitive anticholinergic effects were considered to be definite anticholinergics (ACB score 2-3). 
*Anticholinergic burden CNS symptoms are: Delirium, agitation, disorientation, and visual hallucinations. Ataxia, choreoathetosis, myoclonus and 
seizures may also occur without peripheral symptoms. 
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In the records reviewed, cardiovascular diseases (CVD) were 
present in 51% (n=332) of all patients. Approximately 17.9 million 
people died from CVDs in 2016 and it is known to be the largest 
cause of death worldwide [26]. It is widely acknowledged that 
experiencing a major cardiac event can increase the risk of 
developing mental health problems such as depression [27]. Corell 
et al. stated that in patients with severe MIH such as schizophrenia, 
bipolar affective disorder and major depressive disorder, the risk of 
CVD increased by 2-3X compared to the general population [28, 29]. 
A meta-analysis by Barth et al. analysed 29 studies involving HF 
patients and concluded that patients diagnosed with depression and 
myocardial infarction had a 2 to 2.6 times greater risk of death than 
those without a depression diagnosis [30]. A large observational 
study of 1,937,360 adults with no history of CVD found that 
depression was associated with an increased risk of HF development 
even in healthy patients. The researchers also claimed that there 
was no difference in the risk of suffering from 12 different CVDs 
contrasting with the claims of other researchers [31]. 
Studies suggest the medication patients take can be the reason for 
the increased susceptibility to physical illness such as CVD [28]. For 
example; weight gain is a common side effect of antipsychotic drugs 
affecting up to 72% of patients during the initiation and 
maintenance phase of treatment.<sup>32, 33</sup>It has been 
established that depression is common in patients who experienced 
a stroke and can present up to 2-3 y post the acute event [34]. This 
post-stroke depression may be of biological origin due to neuronal 
damage causing a reduction in neurotransmitter release in the 
catecholamine pathway [35, 36]. The incidence of Dementia post 
stoke was investigated by Ivan et al., who studied 212 subjects who 
were dementia-free in January 1982, and had their first stroke after 
this date. They found that after a 10 y follow up 19.3% of these 
participants developed dementia compared to 11% of controls. They 
postulated this may be due to atherosclerotic disease.  
Diabetes 
In the records reviewed, diabetes constituted 25% (n=160) of all 
patients. WHO estimates that diabetes will affect more than 350 
million persons worldwide by 2030 [37] and that the number of 
people who have diabetes would double in the year 2000 [37]. In 
2014, 8.5% of adults aged 18 y and older had diabetes. In 2016, it 
was the documented cause of 1.6 million deaths and it is estimated 
642 million people worldwide will have diabetes by 2040 [38]. The 
rate of depression among people living with diabetes through their 
lifetime is 2X greater than that of the general population [37, 39]. 
Diabetes distress is defined as the psychological distress specific to 
living with diabetes [40, 41] It is estimated that this may affect as 
many as one in four people living with type 1 diabetes mellitus and 
one in five people with type 2 [42]. Factors such as feeling guilt 
when self-management does not control the disease, concern about 
the possibility of serious complications or being overwhelmed with 
the complexity of their diabetes treatment regimen and life-long 
commitment are the main causes of diabetes-related distress [40, 
41]. The result of diabetes-related depression can be long-term and 
result in lack of self-care and non-adherence to medication [40, 42]. 
Anxiety affects about 30% of the adult population [43]. People living 
with diabetes report increased anxiety and anxiety disorder but the 
overall prevalence in diabetes is similar to the general populace [42]. 
Around 14% of people with diabetes have generalized anxiety, 
which results in poor glycaemic control [37]. Additionally, people 
with diabetes have a greater tendency to be involved in behaviours 
associated with eating disorders [44, 45] People with Type 1 
diabetes sometimes engage in ‘Diabulimia’, aiming for weight loss 
[42, 46]. This can have a dangerous effect on health and life. 
Depression itself has a high co-morbidity with eating disorders [47]. 
Individuals with type 2 diabetes are sometimes associated with 
night eating syndrome (NES). This is when an individual eats more 
than 25% of their daily caloric intake after the evening meal, waking 
up at night to eat, on average, at least 3 times a week [47]. This can 
result into weight gain, poor control of their diabetes and 
complications resulting from this. NICE UK states that dementia 
affects 850,000 people within the UK today, projected to reach over 
1 million by 2025 [7]. Cukierman et al. found a considerable decline 
in cognitive function in patients with diabetes compared to patients 
without diabetes (1.6X) [48]. These findings were also supported by 
Biessels et al. who stated that diabetes is a condition associated with 
hypertension and atherosclerotic disease that contribute to 
cognitive decline through cerebrovascular disease [49]. 
Parkinson disease 
In the records reviewed, there were 1% (n=4) of all patients 
diagnosed with Parkinson’s disease (PD). PD affects 2-3% of the 
population 65 y old and over [50]. Mood disturbance, anxiety, 
depression are the most common in PD [51]. Studies focussing on 
depression as a symptom in people diagnosed with PD, found that 
40–50% of all PD patients are affected by MIH [52]. Treatment of 
depression in PD patients has frequently been poor at around 26%, 
often due to the lack of diagnosis because of overlapping symptoms 
[52]. Findings suggest the use of traditional first-line agents such as 
SSRIs are the favoured option in terms of efficacy and tolerability 
[53]. Patients with PD are 2-6X more likely to develop dementia than 
healthy controls. PD dementia can affect 50% of patients within 
whom mild cognitive impairment becomes gradually worse with 
time [51]. This correlation was noted by Aarsland et al., who found 
that more than 75% of his study cohort of PD patients developed 
dementia during their 8 y study [54]. 
Rheumatoid arthritis 
In the records reviewed, there were 2% (n=8) of all patients 
diagnosed with Rheumatoid arthritis (RA). RA is a common chronic 
inflammatory disease presenting between the ages of 20 and 40 y of 
age [55, 56]. RA is associated with pain, an increase in comorbid 
risks, musculoskeletal deficits, decline in physical function, 
socialization and quality of life [56, 57]. The prevalence of RA varies 
between 0.3% and 1%; and is more common in women and in 
developed countries.[56] WHO states that within 10 y of onset, at 
least 50% of patients in developed countries are unable to 
undertake full-time work [56]. RA is associated with an increased 
prevalence of both depression and anxiety [58, 59]. Jacob et al., 
found that in their study sample of RA patients, 23.7% of men and 
36% of women developed depression [55]. A meta-analysis of 72 
studies concluded that depression and RA comorbidity is associated 
with poorer RA outcomes [60]. Lwin et al. specify that depression is 
higher in RA than the general population by 2X [61]. One study 
highlighted that in their sample, 11% (13 out of 123) experienced 
suicidal ideation [62]. Patients with RA of more than four years 
duration are more likely to report suicidal ideation (12%) vs those 
with less than two years duration (7%) [63]. Finally, Vallerand et al. 
reported that RA and depression comorbidity affect patients’ coping 
strategies, medication compliance and the effectiveness of 
treatment; increasing the risk of disease flares and decreasing the 
rates of remission [64]. The effect of disease-modifying anti-
rheumatic drugs (DMARDS) on the development of dementia in 
patients diagnosed with RA was identified [65]. They found that 
patients who used methotrexate, hydroxychloroquine and 
leflunomide had a 1.63X higher risk of dementia than patients who 
did not take these drugs.  
Respiratory disease 
In the records reviewed, respiratory conditions constituted 27% 
(n=178) of all patients. Psychological disorders, in particular 
depression and anxiety, have been shown to have a close link to 
asthma and COPD [66, 67]. Distress and powerful emotions can 
increase the risks of a person diagnosed with asthma developing 
anxiety [68]. COPD has been associated with increased exhaustion, 
which decreases exercise tolerance. This can hinder a patient from 
carrying out basic daily activities increasing the risk of developing 
depression and anxiety [69]. Yohannes found that anxiety and 
depression was more frequent in COPD patients who smoked, 
compared to those who did not [70]. Atlantis et al. (2013) concluded 
that depression and anxiety could worsen COPD worse in patients 
and precipitate exacerbations [71]. COPD could also increase the risk 
of developing depression. Janssen et al. found results that support 
the connection between dyspnea and depression. They established 
depression was more common in those patients who had severe 
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shortness of breath [72] Liao et al. stated that patients with COPD 
have a greater risk of developing dementia compared to non-COPD 
patients with the risk increasing with increasing age [73]. 
CONCLUSION 
The Pharmaceutical Services Negotiating Committee states that 
approximately 1.6 million people visit a pharmacy in England every 
day. These encounters range from seeking general advice to 
discussing complex long-term health conditions and other co-
morbidities. In addition; community pharmacists are open for 
extended hours; often including weekends in contrast to other 
health care premises. The utilization of community pharmacists and 
their staff can help in addressing the rising challenge of the long-
term health conditions and MIH comorbidities.  
It is was proven during the COVID-19 that pharmacists are in good 
position as easy accessible health care facilities to support patients 
especially when the other NHS facilities are overwhelmed or closed. 
It is recommended that the New Medicines Service include mental 
health disorders patients prescribed pharmacological therapy and to 
allow the pharmacists appropriate access to medical records to 
deliver safe, integrated and effective patient care. Additionally, 
community pharmacies are in a position to offer large-scale 
screening programs such as self-completed anxiety, depression and 
cognitive function screening surveys and refer to general 
practitioners for further investigations. 
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